Stockscreener 앱 받기
28.98
5.85%
-1.80
시간 외 거래:
29.20
0.22
+0.76%
전일 마감가:
$30.78
열려 있는:
$31.32
하루 거래량:
133.07K
Relative Volume:
2.15
시가총액:
$615.65M
수익:
$54,000
순이익/손실:
$-210.26M
주가수익비율:
-36.68
EPS:
-0.79
순현금흐름:
$-159.01M
1주 성능:
-17.41%
1개월 성능:
+39.26%
6개월 성능:
+207.32%
1년 성능:
+124.65%
1일 변동 폭
$27.22
$31.32
1주일 범위
$27.22
$37.00
52주 변동 폭
$7.65
$45.00
Lyell Immunopharma Inc Stock (LYEL) Company Profile
명칭
Lyell Immunopharma Inc
전화
650 695-0677
주소
201 HASKINS WAY, SOUTH SAN FRANCISCO
LYEL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
28.98 | 653.89M | 54,000 | -210.26M | -159.01M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-10-30 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-06-27 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-08-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-11-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-11 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-10-17 | 개시 | H.C. Wainwright | Buy |
| 2021-07-12 | 개시 | BofA Securities | Buy |
| 2021-07-12 | 개시 | Goldman | Buy |
| 2021-07-12 | 개시 | JP Morgan | Overweight |
| 2021-07-12 | 개시 | Morgan Stanley | Overweight |
모두보기
Lyell Immunopharma Inc 주식(LYEL)의 최신 뉴스
Lyell Immunopharma (NASDAQ:LYEL) Shares Down 4.6%Here's Why - MarketBeat
Should I hold or sell Lyell Immunopharma Inc. stock in 2025Market Profile Overview & Low Cost Wealth Investment - bollywoodhelpline.com
Lyell Immunopharma (NASDAQ:LYEL) Shares Up 4.2%Still a Buy? - MarketBeat
Lyell Immunopharma (NASDAQ:LYEL) Trading Down 6.7% – Should You Sell? - Defense World
Lyell Immunopharma (NASDAQ:LYEL) Shares Down 6.7%Here's Why - MarketBeat
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar - sharewise.com
Critical Review: Lipocine (NASDAQ:LPCN) & Lyell Immunopharma (NASDAQ:LYEL) - Defense World
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow - Yahoo Finance
Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data (NASDAQ:LYEL) - Seeking Alpha
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge - GlobeNewswire
Lyell Immunopharma (NASDAQ:LYEL) Shares Up 5.5%Here's Why - MarketBeat
Lyell ImmunoPharma pops on recent ASH data, immunotherapy expansion - MSN
Lyell Immunopharma (NASDAQ:LYEL) Reaches New 1-Year HighTime to Buy? - MarketBeat
Lyell Immunopharma pops on recent ASH data, immunotherapy expansion - Seeking Alpha
Why Lyell Immunopharma Inc. stock could be next big winnerPortfolio Growth Summary & High Win Rate Trade Tips - Улправда
Will Lyell Immunopharma Inc. stock rally after Fed decisionsGold Moves & High Accuracy Swing Trade Signals - Улправда
Dip Buying: Is Lyell Immunopharma Inc. stock a smart buy before Fed meeting2025 Market Trends & Free Expert Verified Stock Movement Alerts - Улправда
What technical charts say about Lyell Immunopharma Inc. stock2025 Trading Recap & Risk Controlled Stock Pick Alerts - DonanımHaber
What analysts say about Lyell Immunopharma Inc stockGap Up/Gap Down Analysis & Free Rapid Wealth Building - earlytimes.in
CEO Change: Why Lyell Immunopharma Inc. stock could be next big winnerBond Market & Consistent Profit Trading Strategies - Улправда
Can Lyell Immunopharma Inc. stock reach $100 price target2025 Earnings Impact & Daily Profit Focused Screening - DonanımHaber
Is Lyell Immunopharma Inc. stock a safe buy before earningsPortfolio Gains Summary & AI Powered Buy and Sell Recommendations - Улправда
Why Lyell Immunopharma Inc. stock could outperform in 20252025 Major Catalysts & Intraday High Probability Setup Alerts - DonanımHaber
Is Lyell Immunopharma Inc. stock a smart buy before Fed meetingJuly 2025 Chart Watch & Technical Pattern Recognition Alerts - Улправда
Lyell Immunopharma (LYEL) details 1.9M-share ICT resale and license terms - Stock Titan
Institutional investors are Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) biggest bettors and were rewarded after last week's US$72m market cap gain - Yahoo Finance
Lyell Immunopharma climbs after reporting strong CAR T-cell therapy results - MSN
China Universal Asset Management Co. Ltd. Has $26,000 Position in Lyell Immunopharma, Inc. $LYEL - Defense World
HSG Holding Ltd Cuts Position in Lyell Immunopharma, Inc. $LYEL - MarketBeat
1,820,634 Shares in Lyell Immunopharma, Inc. $LYEL Bought by ARCH Venture Management LLC - MarketBeat
Lyell ImmunoPharma announces new data from trial of rondecabtagene autoleucel - MSN
Lyell Immunopharma (NASDAQ:LYEL) Sets New 12-Month HighShould You Buy? - MarketBeat
Aug Technicals: Why Lyell Immunopharma Inc stock could outperform in 2025Weekly Gains Summary & Smart Swing Trading Alerts - moha.gov.vn
Lyell Immunopharma (NASDAQ:LYEL) Trading Up 11.4%Should You Buy? - MarketBeat
100,000 Shares in Lyell Immunopharma, Inc. $LYEL Bought by RBF Capital LLC - MarketBeat
Lyell Immunopharma Shares Rise After HC Wainwright Upgrade - marketscreener.com
H.C. Wainwright upgrades Lyell to 'buy' on cell therapy progression - TradingView — Track All Markets
Lyell Immunopharma (LYEL) price target increased by 35.71% to 19.38 - MSN
This Eaton Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors - GlobeNewswire Inc.
LYEL Analyst Rating Upgrade: HC Wainwright & Co. Sets New Price Target | LYEL Stock News - GuruFocus
HC Wainwright & Co. Upgrades Lyell Immunopharma (LYEL) - Nasdaq
Lyell Immunopharma stock rises on strong cancer therapy trial data By Investing.com - Investing.com Australia
Lyell Immunopharma stock rises on strong cancer therapy trial data - Investing.com
Lyell Immunopharma Presents Promising CAR T-Cell Data - TipRanks
Lyell Immunopharma Presents New Data on Ronde-cel at ASH Meeting - TradingView — Track All Markets
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition - The Manila Times
LYEL FinancialsIncome Statement - Quiver Quantitative
Lyell Immunopharma modernizes bylaws for shareholder engagement - MSN
Lyell Immunopharma (Nasdaq: LYEL) posts 76% complete responses with ronde-cel in LBCL - Stock Titan
Lyell Immunopharma (NASDAQ:LYEL) Sets New 12-Month High – Here’s What Happened - Defense World
Lyell Immunopharma Inc (LYEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.57%
자본화:
|
볼륨(24시간):